About: COVID-19 pandemic: A review based on current evidence

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 pandemic: A review based on current evidence Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 pandemic: A review based on current evidence
Creator	Medhi, Bikash Prakash, Ajay Sarma, Phulen Kaur, Harpinder Kaur, Sukhmeet Mahalmani, Vidya Mahendru, Dhruv Semwal, Ankita
Source	Medline; PMC
abstract	In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel coronavirus, initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide. The clinical characteristics of the disease range from asymptomatic cases or mild symptoms, which include nonspecific symptoms such as fever, cough, sore throat, headache, and nasal congestion to severe cases such as pneumonia, respiratory failure demanding mechanical ventilation to multi-organ failure, sepsis, and death. As the transmission rate is quite alarming, we require an effective therapeutic strategy to treat symptomatic patients and adopt the preventive measures in order to contain the infection and prevent community transmission. Coronavirus disease 2019 (COVID-19) pandemic is a public health emergency of international concern, hence repurposing of the drugs is an attractive and a feasible option because PK/PD profile, toxicity profile, and drug interactions are already known. This review emphasizes on the different aspects of COVID-19 such as the epidemiology, etiopathogenesis, diagnosis, and preventive measures to be adopted in order to fight this pandemic. It also highlights upon the ethics preparedness and challenges faced by a developing country like India during such an outbreak. The review focuses on the various approaches adopted till date for developing effective therapeutic strategies including combination of drugs, vaccine therapy, and convalescent plasma therapy to combat this viral outbreak.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.4103/ijp.ijp_310_20
bibo:pmid	32565599
has license	cc-by-nc-sa
schema:url	https://doi.org/10.4103/ijp.ijp_310_20
resource representing a document's title	COVID-19 pandemic: A review based on current evidence
has PubMed Central identifier	PMC7282680
has PubMed identifier	32565599
schema:publication	Indian J Pharmacol
resource representing a document's body	covid:PMC7282680#body_text
is schema:about of	named entity 'based' named entity 'SARS outbreak' named entity 'WHO' named entity 'bronchoalveolar lavage' named entity 'Phase 2' named entity 'Guangdong' named entity 'COVID' named entity 'Nipah virus' named entity 'host cell' named entity 'supportive care' named entity 'infection' named entity 'vaccines' named entity 'vector' named entity 'clinical trial' named entity 'infectious diseases' named entity 'Hunan' named entity 'kidney' named entity 'Ebola' named entity 'QT prolongation' named entity 'therapeutic agents' named entity 'remdesivir' named entity 'COVID' named entity 'antiviral drug' named entity 'hypertension' named entity 'early access' named entity 'IFN' named entity 'antiviral activity' named entity 'TNF inhibitor' named entity 'infection' named entity 'co-infection' named entity 'lactate dehydrogenase' named entity 'FDA' named entity 'lung' named entity 'Arsenicum album 30' named entity 'infection' named entity 'clinical studies' named entity 'Ebola outbreak' named entity 'infection' named entity 'protease' named entity 'SARS-CoV-2' named entity 'viral load' named entity 'Sharbat' named entity 'protein' named entity 'Janus Kinase inhibitor' named entity 'sepsis' named entity 'CDSCO' named entity 'chlorine' named entity 'ARDS' named entity 'diabetes mellitus' named entity 'cough' named entity 'tested positive for COVID-19' named entity 'angiotensin II receptor blockers' named entity 'vaccine' named entity 'immune response' named entity 'SARS' named entity 'complement' named entity 'teicoplanin' named entity 'diabetes mellitus' named entity 'infection' named entity 'mortality rate' named entity 'COVID' named entity 'evolution' named entity 'RNA sequence' named entity 'upregulation' named entity 'SARS-CoV-2' named entity 'false-positive' named entity 'ICMR' named entity 'clinical trial' named entity 'HCQ' named entity 'asymptomatic' named entity 'ARDS' named entity 'infection' named entity 'nonstructural proteins' named entity 'diffuse alveolar damage' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software